tetano
Editor, Senior Moderator
Sci Rep
. 2020 Aug 4;10(1):13093.
doi: 10.1038/s41598-020-70143-6.
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
Franck Touret[SUP] 1 [/SUP], Magali Gilles[SUP] 2 [/SUP], Karine Barral[SUP] 3 [/SUP], Antoine Nougair?de[SUP] 2 [/SUP], Jacques van Helden[SUP] 4 5 [/SUP], Etienne Decroly[SUP] 6 [/SUP], Xavier de Lamballerie[SUP] 2 [/SUP], Bruno Coutard[SUP] 7 [/SUP]
Affiliations
Abstract
A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2 < EC50 ≤ 20 ?M. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study provides information for the selection of drugs to be further validated in vivo. Disclaimer: This study corresponds to the early stages of antiviral development and the results do not support by themselves the use of the selected drugs to treat SARS-CoV-2 infection.
. 2020 Aug 4;10(1):13093.
doi: 10.1038/s41598-020-70143-6.
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
Franck Touret[SUP] 1 [/SUP], Magali Gilles[SUP] 2 [/SUP], Karine Barral[SUP] 3 [/SUP], Antoine Nougair?de[SUP] 2 [/SUP], Jacques van Helden[SUP] 4 5 [/SUP], Etienne Decroly[SUP] 6 [/SUP], Xavier de Lamballerie[SUP] 2 [/SUP], Bruno Coutard[SUP] 7 [/SUP]
Affiliations
- PMID: 32753646
- DOI: 10.1038/s41598-020-70143-6
Abstract
A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2 < EC50 ≤ 20 ?M. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study provides information for the selection of drugs to be further validated in vivo. Disclaimer: This study corresponds to the early stages of antiviral development and the results do not support by themselves the use of the selected drugs to treat SARS-CoV-2 infection.